SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ENGN

enGene Therapeutics Inc. (NASDAQ:ENGN)

CA · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.74-$0.02 (-1.14%)
 
Market cap
$117M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 1, 2022
Website
Market Cap$116.61M-76.5%
Revenue (ttm)$0
Net Income-$4.90M+94.8%
EPS-$0.28+85.3%
Shares Out67.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateFeb 2, 2015
Volume556,716
Open$1.74
Previous Close$1.76
Day's Range$1.69 - $1.79
52-Week Range$1.40 - $12.25
Betan/a
AnalystsBuy
Price Target$4.33(+148.85%)
Earnings DateDec 22, 2026

About ENGN

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Address
4868 Rue Levy, Montreal, QC, H4R 2P1, CA
Market Cap
117 million
Employees
82
Industrial Classification
Biotechnology

enGene Therapeutics Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
3rd Percentile Overall Score
ENGN InsiderScore:33 / 99

enGene Therapeutics Inc. scored higher than 3% of companies evaluated by InsiderBuying, and ranked 90th out of 101 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at enGene Therapeutics Inc. bought $10.1K of stock across 1 purchase in the last 90 days, the largest of them $10.1K.

Stake Increase

None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$10.05K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy1 Hold0 SellAvg target $7.67 (+314.6%)

4 firms rating ENGN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From ENGN’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-1.14%
5 Days
-25.00%
1 Month
+10.13%
6 Months
+6.10%
1 Year
-76.52%

$ENGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ENGN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ENGN's directors and management

Net Shares Purchased by Insiders−6k−3k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ENGN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ENGN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ENGN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ENGN

AVSCAvantis U.S. Small Cap Equity ETF$8.85K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ENGN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
28.44
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
78

News check: Analyst upgrade to Outperform, positive pivotal trial data updates, and planned BLA submission generate bullish sentiment.

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$10.05K
Distinct Buyers
1

Insider Score Trend Over Time

-19.7 since Sep 25
0255075100Sep 25 — Insider Score 48.1Sep 26 — Insider Score 48.1Sep 27 — Insider Score 48.1Sep 28 — Insider Score 48.2Sep 29 — Insider Score 47.5Sep 30 — Insider Score 47.4Oct 1 — Insider Score 46.6Oct 2 — Insider Score 41.0Oct 3 — Insider Score 46.5Oct 4 — Insider Score 46.6Oct 5 — Insider Score 46.5Oct 6 — Insider Score 45.7Oct 7 — Insider Score 45.6Oct 8 — Insider Score 45.4Oct 9 — Insider Score 45.1Oct 10 — Insider Score 44.7Oct 11 — Insider Score 45.5Oct 12 — Insider Score 45.4Oct 13 — Insider Score 45.1Oct 14 — Insider Score 44.8Oct 15 — Insider Score 44.6Oct 16 — Insider Score 44.3Oct 17 — Insider Score 44.3Oct 18 — Insider Score 44.6Oct 19 — Insider Score 44.3Oct 20 — Insider Score 44.4Oct 21 — Insider Score 44.2Oct 22 — Insider Score 44.1Oct 23 — Insider Score 44.1Oct 24 — Insider Score 44.0Oct 25 — Insider Score 43.6Oct 26 — Insider Score 43.5Oct 27 — Insider Score 43.6Oct 28 — Insider Score 43.5Oct 29 — Insider Score 43.1Oct 30 — Insider Score 42.0Oct 31 — Insider Score 41.5Nov 1 — Insider Score 41.8Nov 2 — Insider Score 41.8Nov 3 — Insider Score 40.9Nov 4 — Insider Score 40.4Nov 5 — Insider Score 39.6Nov 6 — Insider Score 38.1Nov 7 — Insider Score 37.5Nov 8 — Insider Score 38.4Nov 9 — Insider Score 38.6Nov 10 — Insider Score 37.2Nov 11 — Insider Score 36.3Nov 12 — Insider Score 36.2Nov 13 — Insider Score 35.0Nov 14 — Insider Score 34.0Nov 15 — Insider Score 34.5Nov 16 — Insider Score 34.0Nov 17 — Insider Score 32.6Nov 18 — Insider Score 31.4Nov 19 — Insider Score 30.4Nov 20 — Insider Score 28.5Nov 21 — Insider Score 27.9Nov 22 — Insider Score 28.4Sep 25Oct 24Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.